Literature DB >> 2620688

Coronary flow increases induced by adenosine and adenine nucleotides are mediated by the coronary endothelium: a new principle of the regulation of coronary flow.

S Nees1.   

Abstract

Intracoronary adenosine as well as the adenine nucleotides (ATP, ADP, AMP, beta, gamma-methylene-ATP, diadenosine-tetraphosphate, and polyadenylic acid) do not elicit their dilatory effects directly at the smooth muscle cells of the resistance vessel wall, but indirectly, via the endothelium. This must be concluded, since for these compounds the coronary endothelium represents an impermeable barrier between intra-arterial and intra-capillary spaces on the one hand, and the interstitium on the other. Furthermore, in equimolar concentrations the substances investigated induce quantitatively very similar increases in flow, although they are characterized by a highly differing metabolism during their passage through the coronary system as well as by great differences in molecular weight. These endothelium-dependent reactions cannot be influenced by 10(-4)M methylene blue, 10(-5)M haemoglobin, or pre-perfusion with 10(-6)M indomethacin. Accordingly, neither the EDRF nitric oxide nor PGI2 can be considered to be the mediator of these particular increases. There are now, however, observations indicating that the coronary endothelium and the smooth muscle cells of the coronary resistance vessels act as an electrically communicating 'syncytium'. In the light of these recent discoveries, a new principle of coronary flow regulation is suggested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2620688     DOI: 10.1093/eurheartj/10.suppl_f.28

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

1.  A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine.

Authors:  E Snoeck; P Jacqmin; A Van Peer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

2.  Species differences in adenosine metabolic sites in the heart.

Authors:  M Borgers; F Thoné
Journal:  Histochem J       Date:  1992-07

Review 3.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

4.  Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.

Authors:  Peter Wielepp; Detlev Baller; Ulrich Gleichmann; Ewa Pulawski; Dieter Horstkotte; Wolfgang Burchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-31       Impact factor: 9.236

5.  The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs.

Authors:  C L Wainwright; J R Parratt; H Van Belle
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

Review 6.  Diverse factors influencing angiotensin metabolism during ACE inhibition: insights from molecular biology and genetic studies.

Authors:  K Morgan
Journal:  Br Heart J       Date:  1994-09

7.  Effects of diadenosine polyphosphates, ATP and angiotensin II on membrane voltage and membrane conductances of rat mesangial cells.

Authors:  R Kleta; J Hirsch; S Heidenreich; H Schlüter; W Zidek; E Schlatter
Journal:  Pflugers Arch       Date:  1995-09       Impact factor: 3.657

8.  Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO.

Authors:  P Nieri; E Martinotti; V Calderone; M C Breschi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 9.  Purine metabolism in the heart. Strategies for protection against myocardial ischaemia.

Authors:  K Ver Donck
Journal:  Pharm World Sci       Date:  1994-04-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.